Elliot Wilbur from CIBC asked about Copaxone sales trends in the quarter and about Tysabri: "...Biogen mentioned that Tysabri is beginning to have more of a negative impact on Avonex and it's not obvious in our ex-trends in the quarter, but I am wondering at the margin, are you seeing any signs that Tysabri is beginning to have an impact on the Copaxone franchise, whether it'd be incremental share of new patient starts or incremental share of switches?"
Reply given by Moshe Manor: "I think if you look at the number in the U.S., as you mentioned, there is some kind of shift between the Q2 and Q3, but overall you can see the growth of Copaxone in the U.S., which is more than almost double that of the growth of the total market. And as far as Tysabri goes, actually if you look at Tysabri in value that capture of 5% market share, and if you look at the size of the market share of all the companies, all products in Copaxone, you can realize that Copaxone was the only product that actually increased market share year-over-year, as the other products lost market share. This means that, more so, the prescription for Tysabri went on to expand on the other products and Copaxone really benefited from the continued growth."
Copaxone logs record, blowout sales in 1Q08. So much for the quaint notion that sales had reached a plateau on account of Tysabri. Pricing and the the weak dollar clearly benefited sales to some degree but, all told, these numbers are too big for pricing and currency to be the whole story.
News 
Market Data 
Discover 
AI
